Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 2/3 1

Status

Completed 21Terminated 4Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 3Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 3Anemia 3Myelodysplastic Syndromes 1Leukemia 1Carcinoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Darbepoetin alfa × Clear all
NCT00989092 2014-01-29

Darbepoetin Alfa and Anemia of Cancer

Amgen

Phase 2 Terminated
287 enrolled 21 charts
Classical hematology

Anemia, Carcinoma, Neoplasms

NCT00386152 2013-07-19

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Terminated
235 enrolled 13 charts
Classical hematology

Anemia, Neoplasms

NCT01222195 2012-08-07

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00210002 2006-11-14

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

Institut Claudius Regaud

Phase 2 Terminated
55 enrolled
Classical hematology

Anemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡